Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recently emerged
pathogenic human coronavirus that belongs to the sarbecovirus lineage of the genus …

The Omicron lineage of SARS-CoV-2, which was first described in November 2021, spread
rapidly to become globally dominant and has split into a number of sublineages. BA. 1 …

On 24 th November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B. 1.1.
529 was announced, containing far more mutations in Spike (S) than previously reported …

The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), is an unprecedented global health crisis. However, therapeutic options for …

Two and a half years into the COVID-19 pandemic, we have gained many insights into the
human antibody response to the causative SARS-CoV-2 virus. In this Review, we …

Terminating the SARS-CoV-2 pandemic relies upon pan-global vaccination. Current
vaccines elicit neutralizing antibody responses to the virus spike derived from early isolates …

The race to produce vaccines against severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) began when the first sequence was published, and this forms the basis for …

SARS-CoV-2 has caused over 2 million deaths in little over a year. Vaccines are being
deployed at scale, aiming to generate responses against the virus spike. The scale of the …

The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection has resulted in an unprecedented setback …